Top

Published in:

Open Access 01-06-2018

Fatigue and depressive symptoms improve but remain negatively related to work functioning over 18 months after return to work in cancer patients

Authors: H. F. Dorland, F. I. Abma, S. K. R. Van Zon, R. E. Stewart, B. C. Amick, A. V. Ranchor, C. A. M. Roelen, U. Bültmann

Published in: Journal of Cancer Survivorship | Issue 3/2018

Abstract

Purpose

The aims of this study are to investigate the course of work functioning, health status, and work-related factors among cancer patients during 18 months after return to work (RTW) and to examine the associations between these variables and work functioning over time.

Methods

Data were used from the 18-month longitudinal “Work Life after Cancer” (WOLICA) cohort, among 384 cancer patients who resumed work. Linear mixed models were performed to examine the different courses during 18-month follow-up. Linear regression analyses with generalized estimating equations (GEE) were used to examine the associations and interactions.

Results

Cancer patients reported an increase of work functioning and a decrease of fatigue and depressive symptoms in the first 12 months, followed by a stable course between 12 and 18 months. Cognitive symptoms were stable during the first 18 months. Working hours increased and social support decreased during the first 6 months; both remained stable between 6 and 18 months. Fatigue, depressive, and cognitive symptoms were negatively associated with work functioning over time; working hours and supervisor social support were positively associated.

Conclusions

Interventions to improve cancer patients’ work functioning over time might be promising if they are aimed at reducing fatigue, depressive symptoms, cognitive symptoms, and encouraging supervisor social support.

Implications for Cancer Survivors

It is important to monitor cancer patients not only in the period directly after RTW but up to 18 months after RTW, allowing for timely interventions when needed.

Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH. Cancer survivors: a booming population. Cancer Epidemiol Biomark Prev. 2011;20(10):1996–2005. https://doi.org/10.1158/1055-9965.EPI-11-0729.CrossRef

Ries LAG, Melberg D, Krapcho M, et al. SEER cancer statistics review, 1975-2004. Bethesda: National Cancer Institute; 2007.

Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol. 2011;77:109–30.CrossRef

Moore HCF. An overview of chemotherapy-related cognitive dysfunction, or 'chemobrain. Oncology (Williston Park). 2014;28:797–804.

Kaiser J, Bledowski C, Dietrich J. Neural correlates of chemotherapy-related cognitive impairment. Cortex. 2014;54:33–50. https://doi.org/10.1016/j.cortex.2014.01.010.CrossRefPubMed

Amick BC, Lerner D, Rogers WH, et al. A review of health-related work outcome measures and their uses, and recommended measures. Spine. 2000;25:3152.CrossRefPubMed

Amick BC, Gimeno D. Measuring work outcomes with a focus on health-related work productivity loss. In: Wittink H, Carr D, editors. Pain management: evidence, outcomes, and quality of life: a sourcebook. Amsterdam: Elsevier; 2008. p. 329–43.

Abma FI, van der Klink, Bültmann U. The work role functioning questionnaire 2.0 (dutch version): examination of its reliability, validity and responsiveness in the general working population. J Occup Rehabil. 2013;23:135–47.CrossRefPubMed

Dorland HF, Abma FI, Roelen C, et al. Work functioning trajectories in cancer patients: results from the longitudinal work life after cancer (WOLICA) study. Int J Cancer. 2017;141(9):1751–62. https://doi.org/10.1002/ijc.30876.CrossRefPubMed

10.

Beurskens AJ, Bültmann U, Kant I, et al. Fatigue among working people: validity of a questionnaire measure. Occup Environ Med. 2000;57:353–7.CrossRefPubMedPubMedCentral

11.

Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the patient health questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry. 2015;37(1):67–75. https://doi.org/10.1016/j.genhosppsych.2014.09.009.CrossRefPubMed

12.

Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the patient health questionnaire (PHQ-9): a meta-analysis. Can Med Assoc J. 2012;184(3):E191–6. https://doi.org/10.1503/cmaj.110829.CrossRef

13.

Dorland HF, Abma FI, Roelen CAM, Smink A, Feuerstein M, Amick BC, et al. The cognitive symptom checklist-work in cancer patients is related with work functioning, fatigue and depressive symptoms: a validation study. J Cancer Surviv. 2016;10(3):545–52. https://doi.org/10.1007/s11764-015-0500-9.CrossRefPubMed

14.

Ottati A, Feuerstein M. Brief self-report measure of work-related cognitive limitations in breast cancer survivors. J Cancer Surviv. 2013;7(2):262–73. https://doi.org/10.1007/s11764-013-0275-9.CrossRefPubMed

15.

Calvio L, Peugeot M, Bruns GL, Todd BL, Feuerstein M. Measures of cognitive function and work in occupationally active breast cancer survivors. JOEM. 2010;52(2):219–27. https://doi.org/10.1097/JOM.0b013e3181d0bef7.PubMedCrossRef

16.

Kristensen TS, Hannerz H, Høgh A, Borg V. The Copenhagen psychosocial questionnaire-a tool for the assessment and improvement of the psychosocial work environment. Scand J Work Environ Health. 2005;31(6):438–49. https://doi.org/10.5271/sjweh.948.CrossRefPubMed

17.

Twisk J. Applied longitudinal data analysis for epidemiology, a practical guide. New York: Cambridge University Press; 2003.

18.

Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22(11):2233–9. https://doi.org/10.1200/JCO.2004.08.094.CrossRefPubMed

19.

Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3:S84–90. https://doi.org/10.3816/CBC.2002.s.018.CrossRefPubMed

20.

Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003;3(3):215–22. https://doi.org/10.1007/s11910-003-0081-2.CrossRefPubMed

21.

Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201. https://doi.org/10.1038/nrc2073.CrossRefPubMedPubMedCentral

22.

Duijts SFA, van Egmond MP, Spelten E, van Muijen P, Anema JR, van der Beek AJ. Physical and psychosocial problems in cancer survivors beyond return to work: a systematic review. Psycho-Oncology. 2014;23(5):481–92. https://doi.org/10.1002/pon.3467.CrossRefPubMed

23.

Dorland HF, Abma FI, Roelen CAM, Smink JG, Ranchor AV, Bültmann U. Factors influencing work functioning after cancer diagnosis: a focus group study with cancer survivors and occupational health professionals. Support Care Cancer. 2016;24(1):261–6. https://doi.org/10.1007/s00520-015-2764-z.CrossRefPubMed

24.

Munir F, Burrows J, Yarker J, et al. Women’s perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs. 2010;19:1362–70.CrossRefPubMed

25.

Abma FI, Amick BC, van der Klink JJL, Bültmann U. Prognostic factors for successful work functioning in the general working population. J Occup Rehabil. 2013;23(2):162–9. https://doi.org/10.1007/s10926-012-9410-0.CrossRefPubMed

26.

Leijten F, van den Heuvel S, Geuskens G, et al. How do older employees with health problems remain productive at work?: a qualitative study. J Occup Rehabil. 2013;23:115–24.CrossRefPubMed

27.

Munir F, Randall R, Yarker J, et al. The influence of employer support on employee management of chronic health conditions at work. J Occup Rehabil. 2009;19:333–44.CrossRefPubMed

28.

Detaille SI, Haafkens JA, Van Dijk FJH. What employees with rheumatoid arthritis, diabetes mellitus and hearing loss need to cope at work. Scand J Work Environ Health. 2003;29(2):134–42. https://doi.org/10.5271/sjweh.715.CrossRefPubMed

29.

Ballanger GA. Using generalized estimating equations for longitudinal data analysis. Organ Res Methods. 2004;7(2):127–50. https://doi.org/10.1177/1094428104263672.CrossRef

30.

Amick B, Kasl S. Work stress. In: McDonald C, editor. Epidemiology of work related diseases. London: BMJ Publishing Group; 2000. p. 283–308. https://doi.org/10.1002/9780470695005.ch14.CrossRef

Title: Fatigue and depressive symptoms improve but remain negatively related to work functioning over 18 months after return to work in cancer patients
Authors: H. F. Dorland
F. I. Abma
S. K. R. Van Zon
R. E. Stewart
B. C. Amick
A. V. Ranchor
C. A. M. Roelen
U. Bültmann
Publication date: 01-06-2018
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 3/2018
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-018-0676-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 3/2018

Survivorship care plan outcomes for primary care physicians, cancer survivors, and systems: a scoping review

Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA

Health status of older cancer survivors—results of the PolSenior study

Usability and acceptance evaluation of ACESO: a Web-based breast cancer survivorship tool

Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?

Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only

Keynote webinar | Spotlight on antibody–drug conjugates in cancer